Urodynamic tests are used to examine the function of the bladder, sphincters, and urethra to store and release urine. There are various types of tests that may be needed, depending on the specific ...
The results from two new randomized trials suggest that urodynamic assessment might not be necessary to select patients for stress incontinence surgery. However, whether these findings change clinical ...
Medical Device Network on MSN
FDA clears Bright Uro’s abdominal sensor for evaluating bladder dysfunction
The approval of Bright Uro’s Glean abdominal sensor advances the capabilities of its broader Glean urodynamics system that ...
(HealthDay News) – For women with uncomplicated stress incontinence, preoperative office evaluation alone is noninferior to urodynamic testing with respect to success of treatment at one year. Charles ...
Routine use of urodynamic testing for overactive bladder (OAB) did not improve patient-reported outcomes when combined with comprehensive clinical assessment (CCA), a large randomized trial showed.
Add Yahoo as a preferred source to see more of our stories on Google. A range of other assessments besides the bladder pressure test work just as well in guiding treatment of female incontinence, ...
A wireless device called the UroMonitor enables accurate, noninvasive monitoring of bladder pressure in patients with overactive bladder, reports a pilot study in the July issue of The Journal of ...
Urodynamics plus comprehensive clinical assessment (CCA) showed no superiority over CCA alone in treating women with refractory overactive bladder symptoms. CCA for female incontinence offered equally ...
Bright Uro, a medical device company with a mission to transform care for lower urinary tract dysfunction (LUTD) through ...
Women with ongoing urinary incontinence could avoid invasive bladder pressure tests, as new research shows that a range of non-invasive assessments work just as well in guiding treatment. Led by ...
Trial shows promise: enGene’s gene therapy for high-risk, BCG-unresponsive bladder cancer achieved a 54% complete response rate, with low progression to advanced disease. Device gains clearance: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results